Another 40-week trial (SURPASS-2) in 1879 T2DM patients on metformin monotherapy further demonstrated that Tirzepatide at all doses was superior to the GLP-1 RA, Semaglutide 1 mg once weekly, in reducing HbA1c as well weight from baseline [47]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.